An investigator-initiated registration-directed phase I/II clinical trial of irinotecan hydrochroride for refractory pediatric solid tumors. Background: Cilengitide is a selective αvβ3/αvβ5 integrin ...
Modeling the combined efficacy of rilotumumab (R; AMG 102) plus epirubicin/cisplatin/capecitabine (ECX) for the treatment of locally advanced or metastatic gastric or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results